The Attgeno organization and investment partners
The successful development of Supernitro would not have been possible without the entrepreneurship of the Attgeno founders and their associates. The company has within its management, board of directors and scientific advisory associates not just excellent researchers but also individuals with a history of building successful companies emerging from discoveries in nitric oxide and pulmonary hypertension research.
Attgeno team members are prime contributors to the only two clinical applications originating from the discovery of nitric oxide in 1987. The late Professor Lars E. Gustafsson and Assistant Professor Magnus Persson discovered exhaled nitric oxide (FeNO) and founded the company Aerocrine that developed and commercialized a diagnostic instrument (NIOX®) to monitor asthma treatment. The Swedish asthma diagnostic company Aerocrine was acquired by biotech Circassia for EUR 171 million in June 2015.
Attgeno team scientific advisor Professor Claes Frostell was, together with MSU Professor Warren Zapol, instrumental in the development of inhaled nitric oxide as a treatment for premature infants with respiratory insufficiency. FDA approved inhalation gas INOmax® for the treatment of hypoxic respiratory failure of the term and near-term newborn in 1993.
Attgeno board directors Magnus Persson and Elisabet Lindberg have been contributing parts in building Actelion Ltd, a billion-Euro company with blockbuster drugs for the treatment of chronic pulmonary hypertension. The acquisition of Actelion by Johnson & Johnson for a total purchase price of approximately EUR 24 billion in cash was announced in June 2017.
Thus, the Attgeno team contains the synthesis of world leading experts with a record of successful commercialization of discoveries in the fields of nitric oxide biology and chronic pulmonary hypertension.